Prostate cancer (PCa) is considered the most prevalent malignancy and the second major cause of cancer-related death in males from Western countries. PCa exhibits variable clinical pictures, ranging from dormant to highly metastatic cancer. PCa suffers from poor prognosis and diagnosis markers, and novel biomarkers are required to define disease stages and to design appropriate therapeutic approach by considering the possible genomic and epigenomic differences. MicroRNAs (miRNAs) comprise a class of small noncoding RNAs, which have remarkable functions in cell formation, differentiation, and cancer development and contribute in these processes through controlling the expressions of protein-coding genes by repressing translation or breaking down the messenger RNA in a sequence-specific method. miRNAs in cancer are able to reflect informative data about the current status of disease and this might benefit PCa prognosis and diagnosis since that is concerned to PCa patients and we intend to highlight it in this paper.
Journal of cellular physiology. 2018 Dec 07 [Epub ahead of print]
Shirin Golabi Aghdam, Mehrdad Ebrazeh, Maryam Hemmatzadeh, Narges Seyfizadeh, Arezoo Gowhari Shabgah, Gholamreza Azizi, Negin Ebrahimi, Farhad Babaie, Hamed Mohammadi
Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran., Department of Laboratory Medicine, Shahid Motahari Hospital, Urmia University of Medical Sciences, Urmia, Iran., Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany., Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran., Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran., Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran.